Aridis Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
May 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Highly Dispersible Powders, Compositions and Methods for Preparation (US 9,072,783) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 2 fees due Mar 3 to 24, 2027 · next Mar 3
- 1 fee due May 5, 2027The maintenance fee for Novel Targets of Acinetobacter Baumannii (US 10,463,727) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Aug 2, 2027The maintenance fee for Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation (US 9,249,215) comes due Aug 2, 2027. Unpaid by Feb 2, 2028, it lapses early.
- 2 fees due Sep 30, 2027
Recent changes
- 3 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,637,090 | Gallium Formulation for the Treatment and Prevention of Infectious Diseases In force · High confidence | In force | High confidence | |
| US 9,072,783 | Highly Dispersible Powders, Compositions and Methods for Preparation In force · High confidence | In force | High confidence | |
| US 8,268,354 | Sonic Low Pressure Spray Drying In force · High confidence | In force | High confidence | |
| US 9,249,215 | Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation In force · High confidence | In force | High confidence | |
| US 9,597,387 | Novel Targets of Acinetobacter Baumannii In force · High confidence | In force | High confidence | |
| US 10,398,767 | Novel Targets of Acinetobacter Baumannii In force · High confidence | In force | High confidence | |
| US 10,420,828 | Novel Targets of Acinetobacter Baumannii In force · High confidence | In force | High confidence | |
| US 10,463,727 | Novel Targets of Acinetobacter Baumannii In force · High confidence | In force | High confidence | |
| US 10,603,372 | Novel Targets of Acinetobacter Baumannii In force · High confidence | In force | High confidence | |
| US 10,603,373 | Novel Targets of Acinetobacter Baumannii In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 6 lapsed for an unpaid fee · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 abandoned · 2 no status recorded